建银国际发表报告，维持信达生物(01801.HK) “跑赢大市”评级，目标价由59元升至61元。
该行表示，信达生物2024年业绩超出预期，宣布首次实现非IFRS净利润。扣除基于股份的补偿成本、金融资产和负债的公允价值变动及其他外汇收益(损失)后，信达生物2024年全年非IFRS净利润为1.89亿元人民币，下半年非IFRS净利润为3.75亿元人民币，超出预期。
报告提及，信达生物去年全年总收入为94亿元人民币，去年下半年为54亿元人民币，按年分别增长52%和54%，超出该行预期10%及16%，主要由于更高的许可费收入。2024年总产品收入为82亿元人民币，下半年为44亿元人民币，按年增长44%及35%，符合该行预期。2024年毛利率为84%，下半年为85.9%，超出预期的82%及81.3%，主要由于规模经济和有效的生产成本控制。(ad/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.